^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Biliary Tract Cancer

    Related cancers:
    1d
    CLDN18.2-Targeted Therapy in Gastrointestinal Cancers. (PubMed, Cancers (Basel))
    Finally, we identify current limitations in the field, including inconsistent CLDN18.2 testing criteria, and outline prioritized future directions to optimize integration of CLDN18.2-directed therapies across gastrointestinal cancers. By looking beyond zolbetuximab and incorporating cross-platform comparison, immuno-oncology considerations, and multi-tumor context, this review provides a broad and forward-looking framework to guide clinical application and next-generation research in CLDN18.2-targeted therapy.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression
    |
    Vyloy (zolbetuximab-clzb)
    4d
    A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, Yonsei University
    New P1/2 trial • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • venadaparib (NOV 1401)
    7d
    CA-4948 in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2031 --> Apr 2032 | Initiation date: Oct 2025 --> Feb 2026 | Trial primary completion date: Jan 2030 --> May 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • emavusertib (CA-4948)
    7d
    Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    7d
    Beacon-BTC: A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer (clinicaltrials.gov)
    P3, N=480, Not yet recruiting, J-Pharma Co., Ltd.
    New P3 trial
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • nanvuranlat (JPH203)
    8d
    The real-world clinical effectiveness of durvalumab in advanced biliary tract cancer: a mimic comparative analysis through survival data reconstruction. (PubMed, Front Immunol)
    The TOPAZ-1 study results represented significant advancement in the treatment of advanced biliary tract cancer (BTC) by combining durvalumab with gemcitabine-cisplatin (DGC). Further real-world investigations are still warranted to determine if the DGC regimen has a broader therapeutic indication and to identify predictive markers for survival benefit. Efforts are required to improve the cost-effectiveness of the DGC regimen to facilitate its wider and standardized use.
    Clinical • Retrospective data • Review • Journal • Real-world evidence • PD(L)-1 Biomarker
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    8d
    Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis. (PubMed, BMC Cancer)
    Our findings directly inform clinical guidelines, address gaps in current therapeutic decision-making. Durvalumab or pembrolizumab combined with GC are optimal first-line regimens for advanced BTC, balancing survival benefits and safety. Sintilimab plus anlotinib combined with GC demonstrates superior PFS but requires further validation. While EGFR inhibitors plus chemotherapy demonstrate potential in KRAS wild-type patients, confirmation in large-scale RCTs is required. PD-L1 expression may represent a promising predictive biomarker for response to PD-1 inhibitor therapy.
    Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS wild-type • RAS wild-type
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • Imfinzi (durvalumab) • gemcitabine • Focus V (anlotinib) • Tyvyt (sintilimab) • bintrafusp alfa (M7824)
    9d
    TQB2102-Ib/II-01: A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=103, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2029 | Trial primary completion date: May 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    TQB2102
    9d
    Giant Cell Tumor of Soft Tissue Involving the Common Hepatic Duct: A Case Report and Review of the Literature. (PubMed, Int J Surg Pathol)
    The patient remained well, without local recurrence or metastasis during 6 years of follow-up. The present tumor highlights the rarity of the location, and the diagnostic challenges encountered prior to surgery.
    Journal
    |
    KRT7 (Keratin-7) • CD68 (CD68 Molecule) • KRT19 (Keratin 19) • KRT20 (Keratin 20)
    11d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    15d
    Molecular Mechanisms of the Ubiquitin-Specific Proteases (USPs) Family in Biliary Tract Cancer and Targeted Intervention Strategies. (PubMed, Biomedicines)
    This review systematically summarizes the differential expression profiles of USP family members (e.g., USP1, USP3, USP7, USP8, USP9X, USP21, and USP22) in BTC and their clinical significance, with a focus on elucidating how specific USPs regulate tumor progression through key substrates, including poly(ADP-ribose) polymerase 1 (PARP1), dynamin-1-like protein (DNM1L), and O-GlcNAc transferase (OGT). Furthermore, based on recent advances, we discuss the therapeutic potential of small-molecule USP inhibitors in BTC targeted therapy, providing a theoretical foundation for developing novel precision treatment strategies.
    Review • Journal • PARP Biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • USP22 (Ubiquitin Specific Peptidase 22) • USP1 (Ubiquitin Specific Peptidase 1) • USP7 (Ubiquitin Specific Peptidase 7) • USP9X (Ubiquitin Specific Peptidase 9 X-Linked)
    15d
    Tiliacorinine as a Promising Candidate for Cholangiocarcinoma Therapy via Oxidative Stress Molecule Modulation: A Study Integrating Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation. (PubMed, Antioxidants (Basel))
    Comparative analysis with the MTOR-GDC-0980 complex confirmed consistent interaction patterns, reinforcing the structural stability and specificity of tiliacorinine. These results highlight its strong pharmacological potential and support its candidacy as a promising lead compound for cholangiocarcinoma therapy.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ICAM1 (Intercellular adhesion molecule 1) • MAPK1 (Mitogen-activated protein kinase 1) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    apitolisib (GDC-0980)